Table 1.
Phase III studies with bevacizumab and chemotherapy as first-line treatment of metastatic breast cancer.
| Study | Treatment line | Arms | Patients | Response rate | Progression-free survival | Overall survival | Crossover |
|---|---|---|---|---|---|---|---|
| E2100 (2007) |
First | Paclitaxel q1w +/− Bev 10 mg/kg q2w | 722 | 36.9% versus 21.2% (P < 0.001) | 11.8 versus 5.9 months [HR 0.6 (0.51–0.7)] | 26.7 versus 25.2 months [HR 0.88 (P = 0.16)] | Not allowed |
|
| |||||||
| AVADO (2008) |
First | Docetaxel q3w + Bev 15 mg/kg or Bev 7.5 mg/kg or Placebo q3w | 736 | 64% (P < 0.001) versus 55% (P = 0.07) versus 46% | 10.1 [HR 0.77 (0.64–0.93)] versus 9.0 [HR 0.86 (0.72–1.04)] versus 8.2 months | 30.2 [HR 1.03 (0.7–1.3)] versus 30.8 [HR 1.05 (0.81–1.36)] versus 31.9 months | Allowed |
|
| |||||||
| RIBBON 1 (2009) |
First | Capecitabine q3w + Bev 15 mg/kg q3w or Placebo q3w Anthracycline1/ Taxane2 q3w + Bev 15 mg/kg q3w or Placebo q3w |
1,237 |
35.4% versus 23.6% (P = 0.009) 51.3% versus 37.9% (P = 0.005) |
8.6 versus 5.7 months [HR 0.69 (0.56–0.84)] 9.2 versus 8.0 months [HR 0.64 (0.52–0.80)] |
29.0 versus 21.2 months [HR 0.85 (0.63–1.14)] 25.2 versus 23.8 months [HR 1.03 (0.77–1.38)] |
Allowed |
1Adriamycin or Epirubicin + Cyclophosphamide +/− 5-Fluorouracil q3w; 2Docetaxel or nab-Paclitaxel q3w.
Abbreviations: ORR: overall response rate; PFS: progression-free survival; HR: hazard ratio; LD: low dose; HD: high dose.